First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC ...

Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

According to Research by SNS Insider, the U.S. Peptide Therapeutics Market is Set to Reach USD 35.71 Billion by 2032, Supported by Rising Adoption of Precision Biologics and Advances in Peptide ...

Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Researchers uncovered the foundations of biology by using E. coli as a model organism. But over-reliance on this microbe can lead to knowledge blind spots with implications for antibiotic resistance.

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

insights from industryAmy ShengHead of CROSino Biological In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO program at Sino Biological US Inc., about current developments in the ...